Literature DB >> 10961719

Treatment of chronic hepatitis C with amantadine.

J S Goff1, R M Reveille, J Johnson.   

Abstract

Hepatitis C is usually treated with interferon or a combination of interferon and ribavirin, but these agents have numerous side effects, and interferon must be given by injection three time a week. An alternative oral medication would be a welcome advance for treating hepatitis C. Amantadine has been reported to have the potential to produce viral suppression in patients with hepatitis C. To gain further knowledge about the effects of amantadine on hepatitis C, we treated 24 patients for 3-12 months (average = 5.5 months; median = 4.5 months) with 100 mg amantadine twice daily. Twelve patients had stage 3 or 4 fibrosis on biopsy. Eleven patients had a fall in viral titer, but complete viral suppression was not seen in any patient. Three patients had no viral titer obtained after treatment, but their elevated transaminase levels did not change with treatment. Of the 15 patients with a decrease in enzyme levels, only two patients had normalization. Six patients had side effects during the treatment, but in only one was amantadine stopped solely because of side effects. Based on these results and a literature review, we do not believe amantadine is an effective single agent for the treatment of chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961719     DOI: 10.1023/a:1005516322593

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  2 in total

1.  Treatment of chronic hepatitis C with amantadine.

Authors:  J P Smith
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

2.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

  2 in total
  8 in total

1.  Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.

Authors:  Rudolf E Stauber; Harald Hofer; Franz Hackl; Kurt Schütze; Christian Datz; Karin Hegenbarth; Wolfgang Jessner; Petra Steindl-Munda; Ferenci Peter
Journal:  Wien Klin Wochenschr       Date:  2004-08-31       Impact factor: 1.704

Review 2.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  Amantadine's viral kinetics in chronic hepatitis C infection.

Authors:  Juliana Chan; Kenneth O'Riordan; Thelma E Wiley
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

4.  Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1).

Authors:  Dilek Oguz; Bahattin Cicek; Levent Filik; Bulent Odemis; Mesut Kilic; Engin Altintas; Neslihan Zengin; Emin Altiparmak
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

5.  Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C.

Authors:  P J Thuluvath; A Maheshwari; J Mehdi; K D Fairbanks; L L-W Wu; L G Gelrud; M J Ryan; F A Anania; I F Lobis; M Black
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

Review 6.  Amantadine for chronic hepatitis c: a magic bullet or yet another dead duck?

Authors:  A Craxi; O Lo Lacono
Journal:  J Hepatol       Date:  2001-10       Impact factor: 25.083

Review 7.  Amantadine in treatment of chronic hepatitis C virus infection?

Authors:  J K Lim; D Wooten; R Siegel; R C Cheung
Journal:  J Viral Hepat       Date:  2005-09       Impact factor: 3.728

8.  Treatment of chronic hepatitis C patients not responding to combination therapy with ribavirin and interferon alpha--hype or hope?

Authors:  Wolfgang Vogel
Journal:  Wien Klin Wochenschr       Date:  2004-08-31       Impact factor: 1.704

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.